DK1169057T3 - Anti-HIV-1-vaccine, der omfatter det hele eller en del af HIV-1-Tat-proteinet - Google Patents
Anti-HIV-1-vaccine, der omfatter det hele eller en del af HIV-1-Tat-proteinetInfo
- Publication number
- DK1169057T3 DK1169057T3 DK00918952T DK00918952T DK1169057T3 DK 1169057 T3 DK1169057 T3 DK 1169057T3 DK 00918952 T DK00918952 T DK 00918952T DK 00918952 T DK00918952 T DK 00918952T DK 1169057 T3 DK1169057 T3 DK 1169057T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- vaccine
- protein
- tat protein
- tat
- Prior art date
Links
- 229940033332 HIV-1 vaccine Drugs 0.000 title abstract 2
- 101710149951 Protein Tat Proteins 0.000 title abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108700010908 HIV-1 proteins Proteins 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9904610A FR2792204B1 (fr) | 1999-04-13 | 1999-04-13 | Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1 |
FR9916633A FR2792206B1 (fr) | 1999-04-13 | 1999-12-29 | Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1 |
PCT/FR2000/000938 WO2000061067A2 (fr) | 1999-04-13 | 2000-04-12 | Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1169057T3 true DK1169057T3 (da) | 2005-03-07 |
Family
ID=26234914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00918952T DK1169057T3 (da) | 1999-04-13 | 2000-04-12 | Anti-HIV-1-vaccine, der omfatter det hele eller en del af HIV-1-Tat-proteinet |
Country Status (20)
Country | Link |
---|---|
US (1) | US7087377B2 (da) |
EP (1) | EP1169057B1 (da) |
JP (1) | JP4860823B2 (da) |
KR (1) | KR100725637B1 (da) |
AT (1) | ATE280586T1 (da) |
AU (1) | AU775560B2 (da) |
BR (1) | BR0009758A (da) |
CA (1) | CA2370563C (da) |
DE (1) | DE60015312T2 (da) |
DK (1) | DK1169057T3 (da) |
ES (1) | ES2231178T3 (da) |
FR (1) | FR2792206B1 (da) |
HK (1) | HK1044463B (da) |
HU (1) | HUP0200841A2 (da) |
IL (2) | IL145884A0 (da) |
MX (1) | MXPA01010482A (da) |
NO (1) | NO326603B1 (da) |
PL (1) | PL197666B1 (da) |
PT (1) | PT1169057E (da) |
WO (1) | WO2000061067A2 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100465589B1 (ko) * | 2001-04-20 | 2005-01-13 | 허만욱 | 비만 억제 폴리펩타이드 |
FR2868318B1 (fr) * | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
CA2722240C (en) * | 2008-04-22 | 2016-09-20 | Centre National De La Recherche Scientifique | Tat protein for preventing or treating aids |
CA2755897C (en) * | 2009-03-23 | 2020-01-28 | Nanirx, Inc. | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
WO2011128720A1 (en) * | 2010-04-14 | 2011-10-20 | Mymetics Corporation | Trans-activator of transcription protein |
DK2691530T3 (da) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | Cmv-glycoproteiner og rekombinante vektorer |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
JP6607784B2 (ja) | 2012-12-06 | 2019-11-20 | ピーアイエヌ ファーマ インコーポレイテッド | 免疫抑制性Tat誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
AU2014329393B2 (en) | 2013-10-04 | 2020-04-30 | Pin Pharma, Inc. | Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
US5019510A (en) | 1987-10-28 | 1991-05-28 | Institut Pasteur | Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor |
US5132205A (en) * | 1988-10-07 | 1992-07-21 | Eastman Kodak Company | High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen |
US5461029A (en) * | 1992-04-24 | 1995-10-24 | American Cyanamid Company | Method of treating herpes viral infections using HBNF and MK proteins |
FR2700169B1 (fr) * | 1993-01-04 | 1995-03-24 | Transgene Sa | Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine. |
BR9607659A (pt) * | 1995-03-08 | 1998-12-15 | Neovacs | Composto imunogênio composição processos para preparação de um composto imunogênico de um anticorpo anti-proteína e de um fragmento anticorpo anti-proteína e fragmento |
DE19514089C2 (de) * | 1995-04-13 | 1997-07-10 | Deutsches Krebsforsch | Nachweisverfahren für HIV-TAT |
JPH10212300A (ja) * | 1996-11-26 | 1998-08-11 | Sankyo Co Ltd | ペプチドワクチン |
US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
-
1999
- 1999-12-29 FR FR9916633A patent/FR2792206B1/fr not_active Expired - Lifetime
-
2000
- 2000-04-12 PL PL353033A patent/PL197666B1/pl unknown
- 2000-04-12 ES ES00918952T patent/ES2231178T3/es not_active Expired - Lifetime
- 2000-04-12 DK DK00918952T patent/DK1169057T3/da active
- 2000-04-12 CA CA2370563A patent/CA2370563C/fr not_active Expired - Lifetime
- 2000-04-12 MX MXPA01010482A patent/MXPA01010482A/es active IP Right Grant
- 2000-04-12 WO PCT/FR2000/000938 patent/WO2000061067A2/fr not_active Application Discontinuation
- 2000-04-12 HU HU0200841A patent/HUP0200841A2/hu unknown
- 2000-04-12 PT PT00918952T patent/PT1169057E/pt unknown
- 2000-04-12 IL IL14588400A patent/IL145884A0/xx active IP Right Grant
- 2000-04-12 JP JP2000610400A patent/JP4860823B2/ja not_active Expired - Lifetime
- 2000-04-12 AT AT00918952T patent/ATE280586T1/de active
- 2000-04-12 AU AU39724/00A patent/AU775560B2/en not_active Expired
- 2000-04-12 BR BR0009758-6A patent/BR0009758A/pt not_active Application Discontinuation
- 2000-04-12 DE DE60015312T patent/DE60015312T2/de not_active Expired - Lifetime
- 2000-04-12 EP EP20000918952 patent/EP1169057B1/fr not_active Expired - Lifetime
-
2001
- 2001-10-04 NO NO20014841A patent/NO326603B1/no not_active IP Right Cessation
- 2001-10-11 IL IL145884A patent/IL145884A/en not_active IP Right Cessation
- 2001-10-12 KR KR10-2001-7013031A patent/KR100725637B1/ko active IP Right Grant
-
2002
- 2002-07-09 HK HK02105105.9A patent/HK1044463B/zh not_active IP Right Cessation
-
2004
- 2004-10-21 US US10/969,191 patent/US7087377B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1169057T3 (da) | Anti-HIV-1-vaccine, der omfatter det hele eller en del af HIV-1-Tat-proteinet | |
TR200001553T2 (tr) | HIV-1 Tat veya bunun türevleri. | |
ATE264914T1 (de) | Antivirale proteine, dafür kodierende dna, und deren verwendung | |
BR9812547A (pt) | Proteìnas de fusão compreendendo proteìnas hiv-1 tat e/ou nef | |
BR0108210A (pt) | Vacina contra o vìrus da imunodeficiência humana | |
WO1990015066A3 (fr) | Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus | |
SI0887427T1 (sl) | Pomnozevanje in detekcija HIV-1 in/ali HIV-2 | |
CY1109659T1 (el) | Mva που εκφραζει τροποποιημενα γονιδια φακελλου, gag και pol του ιου hiv | |
TR200201187T2 (tr) | Ters transkriptazın inhibitörleri olarak benzofenonlar | |
HUP0202502A2 (hu) | Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására | |
FR2731013B1 (fr) | Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications | |
CY1111567T1 (el) | Ενδιαμεσα διβενζο (b,f) αζεπινης | |
DK0404625T3 (da) | Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus | |
DK1159278T3 (da) | Inhibitorer af aspartylprotease | |
MX9700414A (es) | Agentes antivirales de difluoroestatona. | |
CY1105629T1 (el) | Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv | |
EA200500533A1 (ru) | Пептидные производные - ингибиторы слияния при вич-инфекции | |
FI911875A (fi) | Kirala 2-(fosfonometoxi) propylguaniner som antivirala aemnen. | |
BR0108723A (pt) | Medicamentos contra doenças viróticas | |
ZA200108398B (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein. | |
HUP9904262A2 (hu) | Fehérjék alkalmazása retrovírus elleni szerként | |
BR0109345A (pt) | Compostos com atividade anti-hiv | |
CY1105997T1 (el) | Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv | |
DK0685235T3 (da) | Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem | |
ES2155515T3 (es) | Derivados de difluorostatona macrociclica utiles como agentes antivirales. |